Search company, investor...

Hotspur Technologies


Acquired | Acquired

Total Raised




About Hotspur Technologies

Hotspur Technologies is a developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company is committed to being responsive to the needs of medical professionals and patients, as well as, delivering high quality value-added products to the marketplace. Hotspur's products are based on technology that opens blood vessels more efficiently and less invasively. On July 18th, 2012, Hotspur Technologies was acquired by Teleflex million.

Headquarters Location

880 Maude Avenue Suite A

Mountain View, California, 94043,

United States

Missing: Hotspur Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hotspur Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hotspur Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hotspur Technologies is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Hotspur Technologies Patents

Hotspur Technologies has filed 15 patents.

patents chart

Application Date

Grant Date


Related Topics




Fluid dynamics, Actuators, Medical equipment, Implants (medicine), Interventional radiology


Application Date


Grant Date



Related Topics

Fluid dynamics, Actuators, Medical equipment, Implants (medicine), Interventional radiology



Latest Hotspur Technologies News

Teleflex Receives FDA Clearance for 150 cm Length Arrow GPSCath Balloon Dilatation Catheters

Jul 29, 2014

Teleflex announces FDA 510(k) clearance for EZ-IO vascular access system Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery , has announced that its subsidiary Hotspur Technologies, Inc. received FDA 510(k) clearance to market the Arrow® GPSCath® Balloon Dilatation Catheters designed for use with .014” guide wires and in 150 cm length. These novel products enable a variety of peripheral vascular procedures to be performed below the knee with one dual function catheter, potentially reducing procedure time, radiation dosage, and expense for both patients and medical professionals. The Arrow® GPSCath® Balloon Dilatation Catheter is the first dual functional balloon dilatation catheter that combines angioplasty with the proprietary VisioValve™ Injection System. This innovative combination enables physicians to perform peripheral below the knee angioplasty and inject physician selected fluids, such as contrast media, while maintaining guide wire position. “With this latest product approval we continue our commitment to enabling medical professionals to perform peripheral access procedures that simplify and improve the doctor and patient experience while reducing health care costs,” said Benson Smith, Chairman, President & CEO of Teleflex. Added Smith, “We are excited to bring this innovative product for use in below the knee peripheral interventions to the market.” About Teleflex Incorporated Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Wayne, PA, Teleflex employs approximately 11,400 people worldwide and serves healthcare providers in more than 150 countries. Additional information about Teleflex can be obtained from the company's website at . Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. Teleflex, GPSCath, Hotspur and VisioValve are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. © 2014 Teleflex Incorporated. All rights reserved. MC-000259 Teleflex Incorporated Treasurer and Vice President, Investor Relations 610-948-2836

Hotspur Technologies Frequently Asked Questions (FAQ)

  • Where is Hotspur Technologies's headquarters?

    Hotspur Technologies's headquarters is located at 880 Maude Avenue, Mountain View.

  • What is Hotspur Technologies's latest funding round?

    Hotspur Technologies's latest funding round is Acquired.

  • How much did Hotspur Technologies raise?

    Hotspur Technologies raised a total of $10.99M.

  • Who are the investors of Hotspur Technologies?

    Investors of Hotspur Technologies include Teleflex, ONSET Ventures, BioStar Capital, Incept and Qualifying Therapeutic Discovery Project.

  • Who are Hotspur Technologies's competitors?

    Competitors of Hotspur Technologies include NeoChord, ALung Technologies, ADVOS, Cagenix, Autonomic Technologies and 11 more.

Compare Hotspur Technologies to Competitors

ThermalTherapeutic Systems

ThermalTherapeutic Systems is currently developing a portable next-generation perfusion device for international distribution.


Antivirals is engaged in the discovery of agents that inhibit replication of human pathogenic viruses.

Corassist Cardiovascular

CorAssist operates as a clinical-stage medical device company. It develops therapeutic products for treating heart failure with preserved ejection fraction. It was founded in 2003 and is based in Haifa, Israel.

Cleveland Heart

Cleveland Heart has partnered with the Cleveland Clinic to develop the next generation of mechanical cardiac circulatory assist devices with the potential to provide a complete range of treatment options for patients suffering from irreversible end-stage heart failure.


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Acorn Cardiovascular

Acorn Cardiovascular is a medical device company pursuing treatments for patients with heart failure. Acorn

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.